Today we were pleased to present positive Phase 2b results from the ALPINE 4 trial of aldafermin in patients with compensated cirrhosis (F4) due to #NASH at AASLD The Liver Meeting in Boston. #TLM23 @AASLDtweets Press release (w/ presentation link): https://t.co/Qo6m0spNYp

We're thrilled to announce today that Jean-Frédéric Viret, Ph.D. has been appointed Chief Financial Officer of NGM Bio! Read more: https://t.co/qclVT0zu3V

At NGM, we believe it is important to take time to celebrate with one another. Last week, we hosted our annual holiday tradition, where Explorers came together for end-of-year festivities including a holiday lunch and highly competitive white elephant gift exchange. #LifeatNGM

It was great to join @ASH_hematology, where we presented a poster & gave an oral presentation on NGM936, an ILT3 x CD3 bispecific T cell engager product candidate for the treatment of #AML & #multiplemyeloma in collaboration with Dr. @fabianaperna. More: https://t.co/69aHgHJcjo

We are pleased to announce preliminary data from the Phase 1 Part 1a monotherapy dose escalation arm of our Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced or metastatic #solidtumors. More: https://t.co/8u2iQHJtLr

At NGM, we pride ourselves on the many traditions that help define our culture. One of our favorites is our Thanksgiving Potluck, where Explorers join one another to feast & have fun. This year, we enjoyed a variety of dishes from our team members & post-Potluck bingo. #LifeatNGM

At #ESMOImmuno22, we’ll be presenting a poster showcasing initial data from the Phase 1a monotherapy dose escalation arm of our ongoing Phase 1/2 trial of product candidate NGM707 in patients with advanced #solidtumors. More: https://t.co/W6UgMHHxcr

At @ASH_hematology, we’ll be presenting the development of a novel bi-specific T-cell engager targeting ILT3 aka NGM936 for the treatment of #AML and #MultipleMyeloma in collaboration with Dr. @fabianaperna. Catch all the details here: https://t.co/RVDXudn1p5

Lead author @RishiJainMD comments on the prelim findings presented at #ESMO21 today from our ongoing NGM120 Phase 1b metastatic #PancreaticCancer combo cohort. Historic median PFS in this patient population is approximately 24 weeks. Read full release: https://t.co/kkOmg42snR

We're pleased to present preliminary findings today at #ESMO21 from our ongoing Phase 1a/1b dose escalation study of NGM120 in patients with advanced #solidtumors. Read release: https://t.co/kkOmg42snR

With #oncology programs targeting ILT2/ILT4, ILT3 & LAIR1, our #myeloid reprogramming strategy is directed at multiple, distinct targets to enhance #antitumor immunity. Latest news: https://t.co/tFs6Ztmc6Y Related @CIR_AACR publication: https://t.co/8qrkHca9AR

We’re thrilled to disclose our 4th #oncology dev candidate, NGM831, an ILT3 antagonist antibody, coinciding w/ our publication in @CIR_AACR describing NGM’s discovery of ILT3’s functional ligand, fibronectin, a key component of the #tumor stroma. Release: https://t.co/tFs6Ztmc6Y

Dr. Arshad Khanani comments on the potential of #complement inhibition to address the significant unmet need of patients with #geographicatrophy ... Read the latest about our Phase 2 CATALINA study of NGM621, our anti-complement C3 antibody: https://t.co/uxWRMTvLWe

We're excited to announce that we've completed enrollment in our Phase 2 CATALINA study of NGM621, our anti-complement C3 antibody, in patients with #geographicatrophy secondary to age-related #maculardegeneration. Read release: https://t.co/uxWRMTvLWe

ICYMI, we announced an amended agreement w/ long-time partner @Merck primarily w/ retinal & CVM focus. We gained WW rights to our disclosed oncology programs & future research programs outside of select Merck targets. Excited for this next chapter! https://t.co/e8Yk0DAIDa

This week we announced the initiation of a Phase 1/2 trial of NGM707 for the treatment of patients with advanced solid #tumors. Our second #oncology program to enter the clinic, NGM707 is a novel ILT2/ILT4 dual antagonistic antibody. Read release: https://t.co/I5IZue0RlV

Dr. Charles Wykoff @TXRetinaSurgeon comments on the unmet need of patients with #geographicatrophy and the advancement of NGM621 into Phase 2 study ...

We're thrilled to announce the initiation of our Phase 2 CATALINA study of NGM621 as a potential treatment for #geographicatrophy, an advanced form of age-related #maculardegeneration. Read release: https://t.co/bsrIbIEvQy

Celebrating with the LGBTQ+ community the landmark #SCOTUS ruling last week that extended workplace discrimination protection to include sexual orientation and gender identity. #HappyPrideMonth

Thrilled to welcome Carole Ho, M.D., CMO & Head of Development @Denalitx to our Board! https://t.co/qNJc0lacGP